Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 6/20 | 0.35 |
| ▸ | CDK2 | P24941 | 5/20 | 0.35 |
| ▸ | CDK9 | P50750 | 5/20 | 0.35 |
| ▸ | CDC7 | O00311 | 3/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.35 |
| ▸ | PAK4 | O96013 | 3/20 | 0.35 |
| ▸ | PRKACA | P17612 | 3/20 | 0.35 |
| ▸ | FLT3 | P36888 | 3/20 | 0.35 |
| ▸ | CLK2 | P49760 | 3/20 | 0.35 |
| ▸ | GSK3B | P49841 | 3/20 | 0.35 |
| ▸ | PRKX | P51817 | 3/20 | 0.35 |
| ▸ | JAK3 | P52333 | 3/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.35 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.35 |
| ▸ | STK3 | Q13188 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.35 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512512 | 0.79 | CYP2C9 (0.42) | JAK2CDK7CDK2CDK9DAPK3 | |
| SCHEMBL1266809 | 0.77 | JAK2 (0.43) | JAK2GSK3BPIK3CAPIK3CDPIK3R1 | |
| SCHEMBL2541038 | 0.70 | CYP2C9 (0.54) | FLT3MAPK1ADORA1 | |
| SCHEMBL1266831 | 0.69 | JAK2 (0.41) | JAK2CDK2CDK9GSK3BPIK3CA | |
| SCHEMBL2545189 | 0.69 | PTGS2 (0.36) | CDK7CDK2CDK9GSK3BJAK3 | |
| SCHEMBL14715718 | 0.68 | KDM1A (0.32) | GSK3BPIK3CA | |
| SCHEMBL1882955 | 0.67 | CYP3A4 (0.45) | FLT3ADORA1 | |
| SCHEMBL2540266 | 0.67 | CYP3A4 (0.42) | CDK7CDK2PIK3CAAKT1MTOR | |
| SCHEMBL1885533 | 0.66 | CYP3A4 (0.48) | FLT3DYRK1A | |
| SCHEMBL3862095 | 0.64 | LCK (0.37) | JAK2PIK3CAROCK1MAPK1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-2560972-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9682981-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2015-07-02 | — | — | US | disclosed |
| US-8901118-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2560972-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133637-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, NTRK1, PRKDC | JAK2 90/4885CDK7 449/4885CDK2 1041/4885 |
| US-20170283423-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, PRKDC, NTRK1 | JAK2 70/4885CDK7 413/4885CDK2 974/4885 |
| US-20150183793-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, PRKDC, NTRK1 | JAK2 72/4885CDK7 392/4885CDK2 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.